Do analysts prefer OGI or GOSS?

Gossamer Bio has a consensus target price of $4.50, indicating a potential upside of 2,498.15%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Organigram Global. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

Do analysts rate MENS or GOSS?

Gossamer Bio has a consensus target price of $4.50, suggesting a potential upside of 2,498.15%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better earnings and valuation, MENS or GOSS?

Jyong Biotech has higher earnings, but lower revenue than Gossamer Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Gossamer Bio $48.47M 0.84 -$170.37M -$0.79 N/A

Is MENS or GOSS more profitable?

Jyong Biotech has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Gossamer Bio -324.82% N/A -96.10%

Does the media favor MENS or GOSS?

In the previous week, Gossamer Bio had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for Gossamer Bio and 2 mentions for Jyong Biotech. Gossamer Bio's average media sentiment score of 0.24 beat Jyong Biotech's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GOSS or ACOG?

In the previous week, Gossamer Bio had 2 more articles in the media than Alpha Cognition. MarketBeat recorded 3 mentions for Gossamer Bio and 1 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.11 beat Gossamer Bio's score of 0.24 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, GOSS or IFRX?

InflaRx has lower revenue, but higher earnings than Gossamer Bio. InflaRx is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gossamer Bio $48.47M 0.84 -$170.37M -$0.79 N/A InflaRx $30K 5,397.65 -$51.63M -$0.71 N/A

Is GOSS or IFRX more profitable?

InflaRx has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Gossamer Bio -324.82% N/A -96.10% InflaRx N/A -88.30% -65.77%

Does the media prefer GOSS or IFRX?

In the previous week, Gossamer Bio had 2 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Gossamer Bio and 1 mentions for InflaRx. Gossamer Bio's average media sentiment score of 0.24 beat InflaRx's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VTVT or GOSS?

In the previous week, vTv Therapeutics and vTv Therapeutics both had 3 articles in the media. vTv Therapeutics' average media sentiment score of 0.33 beat Gossamer Bio's score of 0.24 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Gossamer Bio (GOSS) Competitors

$0.17 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.17 0.00 (-0.69%)

As of 07/2/2026 07:56 PM Eastern

Compare

GOSS vs. OGI, MENS, ACOG, IFRX, and VTVT

Should you buy Gossamer Bio stock or one of its competitors? MarketBeat compares Gossamer Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gossamer Bio include Organigram Global (OGI), Jyong Biotech (MENS), Alpha Cognition (ACOG), InflaRx (IFRX), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.

How does Gossamer Bio compare to Organigram Global?

Organigram Global (NASDAQ:OGI) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Organigram Global has a net margin of -9.22% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Organigram Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram Global	-9.22%	-13.41%	-9.09%
Gossamer Bio	-324.82%	N/A	-96.10%

Organigram Global has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

In the previous week, Gossamer Bio had 3 more articles in the media than Organigram Global. MarketBeat recorded 3 mentions for Gossamer Bio and 0 mentions for Organigram Global. Gossamer Bio's average media sentiment score of 0.24 beat Organigram Global's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Organigram Global	Neutral
Gossamer Bio	Neutral

Organigram Global has higher revenue and earnings than Gossamer Bio. Organigram Global is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$274.19M	0.53	-$17.70M	-$0.13	N/A
Gossamer Bio	$48.47M	0.84	-$170.37M	-$0.79	N/A

Gossamer Bio has a consensus target price of $4.50, indicating a potential upside of 2,498.15%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Organigram Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 0.1% of Organigram Global shares are owned by company insiders. Comparatively, 3.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Gossamer Bio beats Organigram Global on 10 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Gossamer Bio (NASDAQ:GOSS) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, Gossamer Bio had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for Gossamer Bio and 2 mentions for Jyong Biotech. Gossamer Bio's average media sentiment score of 0.24 beat Jyong Biotech's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jyong Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jyong Biotech has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Gossamer Bio	-324.82%	N/A	-96.10%

81.2% of Gossamer Bio shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Jyong Biotech has higher earnings, but lower revenue than Gossamer Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Gossamer Bio	$48.47M	0.84	-$170.37M	-$0.79	N/A

Gossamer Bio has a consensus target price of $4.50, suggesting a potential upside of 2,498.15%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Gossamer Bio beats Jyong Biotech on 8 of the 11 factors compared between the two stocks.

How does Gossamer Bio compare to Alpha Cognition?

Gossamer Bio (NASDAQ:GOSS) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Gossamer Bio has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market.

81.2% of Gossamer Bio shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alpha Cognition has lower revenue, but higher earnings than Gossamer Bio. Alpha Cognition is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.84	-$170.37M	-$0.79	N/A
Alpha Cognition	$10.22M	16.81	-$20.67M	-$1.35	N/A

In the previous week, Gossamer Bio had 2 more articles in the media than Alpha Cognition. MarketBeat recorded 3 mentions for Gossamer Bio and 1 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.11 beat Gossamer Bio's score of 0.24 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gossamer Bio presently has a consensus target price of $4.50, suggesting a potential upside of 2,498.15%. Alpha Cognition has a consensus target price of $14.67, suggesting a potential upside of 85.89%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Alpha Cognition has a net margin of -232.23% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Alpha Cognition	-232.23%	-58.35%	-45.99%

Summary

Gossamer Bio and Alpha Cognition tied by winning 8 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to InflaRx?

Gossamer Bio (NASDAQ:GOSS) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Gossamer Bio had 2 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Gossamer Bio and 1 mentions for InflaRx. Gossamer Bio's average media sentiment score of 0.24 beat InflaRx's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market.

Gossamer Bio currently has a consensus price target of $4.50, indicating a potential upside of 2,498.15%. InflaRx has a consensus price target of $7.00, indicating a potential upside of 212.50%. Given Gossamer Bio's higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

InflaRx has lower revenue, but higher earnings than Gossamer Bio. InflaRx is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.84	-$170.37M	-$0.79	N/A
InflaRx	$30K	5,397.65	-$51.63M	-$0.71	N/A

InflaRx has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
InflaRx	N/A	-88.30%	-65.77%

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

InflaRx beats Gossamer Bio on 9 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

vTv Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. vTv Therapeutics' return on equity of 3.96% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
Gossamer Bio	-324.82%	N/A	-96.10%

vTv Therapeutics currently has a consensus price target of $55.33, suggesting a potential upside of 56.31%. Gossamer Bio has a consensus price target of $4.50, suggesting a potential upside of 2,498.15%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

vTv Therapeutics has higher earnings, but lower revenue than Gossamer Bio. vTv Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$36.84M	3.79	-$26.97M	-$0.93	N/A
Gossamer Bio	$48.47M	0.84	-$170.37M	-$0.79	N/A

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

vTv Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

In the previous week, vTv Therapeutics and vTv Therapeutics both had 3 articles in the media. vTv Therapeutics' average media sentiment score of 0.33 beat Gossamer Bio's score of 0.24 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

vTv Therapeutics beats Gossamer Bio on 9 of the 15 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOSS vs. The Competition

Export

Metric	Gossamer Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.65M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.22	21.61	28.02	24.70
Price / Sales	0.84	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-0.33	8.66	10.96	6.46
Net Income	-$170.37M	$23.81M	$3.57B	$337.01M
7 Day Performance	8.25%	3.39%	2.12%	1.69%
1 Month Performance	-1.03%	10.81%	5.25%	3.81%
1 Year Performance	-85.86%	62.61%	33.29%	23.90%

Gossamer Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOSS Gossamer Bio	3.0293 of 5 stars	$0.17 flat	$4.50 +2,498.2%	-85.9%	$40.65M	$48.47M	N/A	180	Gap Down
OGI Organigram Global	0.3618 of 5 stars	$1.02 -1.0%	N/A	-27.5%	$144.99M	$185.07M	N/A	1,139
MENS Jyong Biotech	N/A	$2.20 +17.0%	N/A	-72.0%	$142.93M	N/A	N/A	31	News Coverage Gap Down
ACOG Alpha Cognition	4.051 of 5 stars	$6.81 +4.8%	$14.67 +115.4%	-24.6%	$141.53M	$10.22M	N/A	N/A	Positive News
IFRX InflaRx	1.9292 of 5 stars	$2.28 +18.8%	$7.00 +207.0%	+178.3%	$138.80M	$30K	N/A	60	Positive News Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Competitors

GOSS vs. OGI, MENS, ACOG, IFRX, and VTVT

How does Gossamer Bio compare to Organigram Global?

Summary

How does Gossamer Bio compare to Jyong Biotech?

Summary

How does Gossamer Bio compare to Alpha Cognition?

Summary

How does Gossamer Bio compare to InflaRx?

Summary

How does Gossamer Bio compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Competitors

GOSS vs. OGI, MENS, ACOG, IFRX, and VTVT

How does Gossamer Bio compare to Organigram Global?

Is OGI or GOSS more profitable?

Which has more volatility & risk, OGI or GOSS?

Does the media prefer OGI or GOSS?

Which has better earnings & valuation, OGI or GOSS?

Do analysts prefer OGI or GOSS?

Do insiders & institutionals have more ownership in OGI or GOSS?

Summary

How does Gossamer Bio compare to Jyong Biotech?

Does the media favor MENS or GOSS?

Is MENS or GOSS more profitable?

Do insiders and institutionals hold more shares of MENS or GOSS?

Which has better earnings and valuation, MENS or GOSS?

Do analysts rate MENS or GOSS?

Summary

How does Gossamer Bio compare to Alpha Cognition?

Which has more risk and volatility, GOSS or ACOG?

Do insiders and institutionals have more ownership in GOSS or ACOG?

Which has higher valuation and earnings, GOSS or ACOG?

Does the media favor GOSS or ACOG?

Do analysts rate GOSS or ACOG?

Is GOSS or ACOG more profitable?

Summary

How does Gossamer Bio compare to InflaRx?

Does the media prefer GOSS or IFRX?

Which has more risk and volatility, GOSS or IFRX?

Do analysts recommend GOSS or IFRX?

Which has stronger earnings and valuation, GOSS or IFRX?

Is GOSS or IFRX more profitable?

Do institutionals & insiders believe in GOSS or IFRX?

Summary

How does Gossamer Bio compare to vTv Therapeutics?

Is VTVT or GOSS more profitable?

Do analysts prefer VTVT or GOSS?

Which has better valuation and earnings, VTVT or GOSS?

Do institutionals & insiders hold more shares of VTVT or GOSS?

Which has more risk and volatility, VTVT or GOSS?

Does the media prefer VTVT or GOSS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools